ABSTRACT
Zika virus (ZIKV) is a mosquito-borne pathogen belonging to Flaviviridae family whose primary transmission occurs via the infected Aedes sp mosquito. The feature that distinguishes this virus from other flaviviruses is related to its transmission. Especially, defining of sexual and transplacental transmission routes for ZIKV makes this virus unique. ZIKV infections generally remain asymptomatic while they can also cause mild febrile disease symptoms such as headache, myalgia, fever, rash and non-purulent conjunctivitis. Currently, there is no FDA approved drug or treatment technique to stop or cure the disease caused by ZIKV. However, many research groups are focusing on treating the ZIKV-associated diseases. DNA based vaccine is a new fashion technology using genetically engineered DNA to take an immunologic response. To succeed this goal, the main strategy is to use DNA plasmids having antigens encoded on them. Cost, long term persistence of immunogenicity, stability properties and inducing protective humoral and cellular immune responses are some advantages of the DNA vaccination.
